CA-THE-OPEN-GROUP
6.1.2022 10:02:04 CET | Business Wire | Press release
Effective January 1st, Energistics Consortium, Inc. is now an affiliate of The Open Group®, a global consortium that enables the achievement of business objectives through technology standards. Energistics remains a separate entity, with The Open Group assuming control of Energistics operations, in a move which will enable broader community access, more efficient collaboration, and stronger standards evolution in line with the global energy transition.
Having proudly served the industry for over thirty years, Energistics is also a long-standing member of The Open Group OSDU™ Forum, and in October 2018 became the first non-operator company to be invited to join the Forum. Its WITSML™ , RESQML™ , PRODML™ , and ETP standards have become universal in the industry and form a critical component of the OSDU Data Platform.
Development will continue in Energistics Special Interest Groups (SIGs) to ensure the standards remain a vibrant part of the Energy community. Most recently, Energistics Transfer Protocol v1.2 was released in September 2021, and a consolidated Release Candidate for new versions of RESEQML, PRODML, and WITSML was made available in December 2021.
This work will support both the wider industry and the ongoing development of the OSDU Data Platform and standards for analyzing legacy subsurface energy data as well as new energy data from wind, geothermal, hydrogen, photovoltaic sources, and carbon capture, utilization, and storage data sources.
“As Energistics starts an exciting new chapter in its development, we want to thank the more than 3,500 upstream subject matter experts, from over 115 member companies, who have contributed to its development over the last thirty years,” said Ross Philo, CEO of Energistics. “We are also particularly grateful to our operational staff, who have served the industry with outstanding dedication. They have ensured a smooth transition for our members, and we wish them all the best in their next adventure.”
Today’s transition of governance reflects the significant overlap between Energistics and The Open Group OSDU Forum, with 42 of the 220 current Forum members also being Energistics members. Retaining its own board, the work of Energistics will now be overseen by members of both organizations alongside The Open Group itself.
“The relationship between Energistics and The Open Group has been a long and fruitful one, and this is the right next step for our organizations,” adds Steve Nunn, CEO and President of The Open Group. “Bringing the knowledge and capabilities of The Open Group OSDU Forum and the Energistics SIGs closer together means that we will continue to lead the charge in data exchange standards for the industry, while also opening doors to a broader community for both organizations. We are committed to ensuring that the Energistics standards continue to evolve, thrive, and enable cross-discipline integration of industry data.”
- ENDS -
About Energistics
Energistics is the leading upstream oil and gas industry's data standards body. We are a global, non-profit consortium established over 30 years ago to bring together industry professionals in a neutral and collaborative environment to develop and deploy open data exchange standards and to address oil and gas information sharing challenges. Our members consist of international and nationalized oil companies, oilfield service companies, hardware and software vendors, system integrators, regulatory agencies, and the global standards user community. For more information, visit our website at www.energistics.org .
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 850 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. Further information on The Open Group can be found at www.opengroup.org .
About The Open Group OSDU Forum
The Open Group OSDU Forum is developing the Open-Source Software OSDU Data Platform and associated standards that enables the Energy industry to develop the transformational technology implementation to support the world's changing Energy needs. The Open Group OSDU Forum has over 225 member organizations and over 1900 subscribers worldwide. Membership in The Open Group OSDU Forum is available to all energy stakeholders including international and nationalized oil companies, new energy providers, application developers, service operators, technology providers, software companies, academia, and more. More information on the OSDU Forum can be found at www.osduforum.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005072/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
